References
- Mirinaviciute G, Quist-Paulsen E, Brantsæter AB, et al. The burden of herpes zoster disease in Norway. Vaccine. 2020;38(18):3501–3507.
- Haugnes H, Flem E, Wisløff T. Healthcare costs associated with varicella and herpes zoster in Norway. Vaccine. 2019;37(29):3779–3784.
- Oxman MN, Levin MJ, Johnson GR, et al. Shingles prevention study group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284.
- Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–928.
- Baxter R, Bartlett J, Fireman B, et al. Long-term effectiveness of the live zoster vaccine in preventing shingles: a cohort study. Am J Epidemiol. 2018;187(1):161–169.
- Aavitsland P. Vaksinasjonsprogram for voksne [Vaccination programme for adults]. Tidsskr Nor Laegeforen. 2019 May 20;139(9). Norwegian. doi: 10.4045/tidsskr.19.0281. PMID: 31140253.
- Norwegian Institute of Public Health. SYSVAK register shows that more and more people over the age of 65 are taking the flu vaccine: Published March 11, 2020. Available at: SYSVAK-registeret viser at stadig flere over 65 år tar influensavaksine - FHI. Accessed 2021 May 14.
- Matthews I, Lu X, Dawson H, et al. Assessing the effectiveness of zoster vaccine live: a retrospective cohort study using primary care data in the United Kingdom. Vaccine. 2018 Nov 12;36(46):7105–7111.
- Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001 Apr 30;19(23–24):3076–3090.
- Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007Nov28;25(49):8326–8337.
- Neumann PJ, Ganiats TG, Russell LB, et al., Editors. Cost-Effectiveness in health and medicine. Second ed. New York: Oxford University Press; 2016.
- Drummond MF, Schulper MJ, Claxton K, et al. Methods for the economic evaluation of health care programmes. Fourth ed. Oxford: Oxford University Press; 2015. p. 2.
- Ethgen O, Standaert B. Population- versus cohort-based modelling approaches. Pharmacoeconomics. 2012 Mar;30(3):171–181.
- Norwegian Medicines Agency. Guidelines for the submission of documentation for single technology assessment (STA) of pharmaceuticals. Updated May 20, 2020. Available at: https://legemiddelverket.no/Documents/English/Public%20funding%20and%20pricing/Documentation%20for%20STA/Guidelines%2020.05.2020.pdf. cited 2020 Jul 15.
- Statistics Norway. 07459: population, by sex and age (5 year interval) 1966 – 2019. 2019. Available at: https://www.ssb.no/en/statbank/table/07459/. cited 2020 Jul 15.
- Statistics Norway. 07902: life tables, by sex and age 1966 – 2019. 2019. Available at: https://www.ssb.no/en/statbank/table/07902/. cited 2020 Jul 15.
- Klein NP, Bartlett J, Fireman B, et al. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019;37(36):5422–5427.
- Popmihajlov Z, Pang L, Brown E, et al. Low rates of severe injection-site and systemic adverse events within 7 days postvaccination with ZOSTAVAX™, a post-hoc analysis of two pivotal phase 3 trials. Presented at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); April 9-12, 2016; Amsterdam, The Netherlands.
- Norwegian Medicines Agency. Statens legemiddelverk. Legemiddelverket.no. Available at: https://www.legemiddelsok.no/sider/Legemiddelvisning.aspx?pakningId=88800fef-5d18-4c94-a6f5-faf64e17ccd2&searchquery=aciclovir&f=Han;MtI;Vir;ATC;Var;Mar;Mid;Avr;gen;par;&pane=1. cited 2020 Jul 15.
- Norwegian Institute of Public Health. Vaccination of adults and risk groups. 2018. Available at: https://www.nsf.no/Content/4136272/cache=1541764950000/Utredning+vaksinasjonsprogram+for+voksne+og+risikogrupper.pdf. cited 2020 Dec 7.
- Helsedirektoratet. ISF, 2020. Available at: https://www.helsedirektoratet.no/tema/finansiering/innsatsstyrt-finansiering-og-drg-systemet/innsatsstyrt-finansiering-isf/ISF-regelverket%202020.pdf/_/attachment/inline/0a14f8c6-2443-4c22-97ce-df83d54ff27e:97c7d54f408ce454ebd38caa957d3e4e8c40a7b0/ISF-regelverket%202020.pdf. cited 2020 Jul 15.
- Drolet M, Levin MJ, Schmader KE, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047–2050.
- Statistics Norway. 11652: employees, jobs, and earnings, by place of work, sex, and age. 2020a. Available at: https://www.ssb.no/en/statbank/table/11652. cited 2020 Jul 15.
- Statistics Norway. 11656: employees and jobs, by sex, age, and industry division. 2020b. Available at https://www.ssb.no/en/statbank/table/11656. cited 2020 Jul 15.
- Sun S, Irestig R, Burstrom B, et al. Health-related quality of life (EQ-5D) among homeless persons compared to a general population sample in Stockholm County, 2006. Scand J Public Health. 2012;40(2):115–125.
- Burstrom K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10(7):621–635.
- Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
- Briggs A, Schulper M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
- Norwegian Ministry of health and Care Services. Principles for priority setting in health care: summary of a white paper on priority setting in the Norwegian health care sector. November 2016. Available at: Principles for priority setting in health care – Summary of a white paper on priority setting in the Norwegian health care sector (regjeringen.no). Accessed 2020 Jul 15.
- Chiyaka ET, Nghiem VT, Zhang L, et al. Cost-effectiveness of herpes zoster vaccination: a systematic review. Pharmacoeconomics. 2019 Feb;37(2):169–200.
- Schmidt-Ott R, Schutter U, Simon J, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: a prospective study. J Infect. 2018 May;76(5):475–482.
- Ultsch B, Köster I, Reinhold T, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ. 2013;14(6):1015–1026.